Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores
Journal of the European Academy of Dermatology and Venereology · 2024
DOI: 10.1111/jdv.19669 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2024. Verfasst von Andreas Wollenberg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Eczema, Azetidines, Purines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Background
Baricitinib treatment in adults with moderate‐to‐severe atopic dermatitis (AD) has demonstrated rapid improvements in itch as well as AD sign severity and affected body surface area as assessed by the Eczema Area and Severity Index (EASI) total score, whether administered as monotherapy or in combination with topical corticosteroids (TCS). As EASI clinical signs differ in time course and associated antecedents, the effects of baricitinib on each individual clinical sign are of interest.
Objectives
In this post hoc analysis, we aimed to investigate the effects of baricitinib on individual EASI subscores, namely excoriation, oedema/papulation, erythema and lichenification, in both monotherapy and TCS combination therapy trials.
Methods
We analysed the percent change from baseline in individual EASI subscores from three phase‐III, double‐blind, 16‐week trials of baricitinib in monotherapy (BREEZE‐AD1/BREEZE‐AD2) and TCS combination therapy (BREEZE‐AD7) cohorts via mixed model repeated measures (MMRM).
Results
Baricitinib 4 mg showed rapid and sustained improvements in all four clinical signs in both cohorts. Significant effects emerged at week 1 for excoriation, oedema/papulation and erythema scores in monotherapy ( p < 0.001) and TCS combination therapy ( p < 0.001, p < 0.01, p < 0.001), plateaued at week 4, and remained significant versus placebo through week 16. The effect on lichenification scores also emerged early, at week 1 in monotherapy ( p < 0.05) and week 2 in combination therapy ( p < 0.001), with scores continuously improving without a clear plateau. Effect magnitude was highest in excoriation scores, exhibiting near‐maximal reduction in week 1 of monotherapy and remaining highest across all timepoints in combination therapy.
Conclusions
Rapid and sustained improvements were observed across clinical signs of inflammation and particularly on excoriation following baricitinib treatment. Our findings suggest that selective inhibition of janus kinases 1 and 2 leads to rapid and sustained control of skin inflammation, and that rapid reductions in itch translate into early disruption of the itch‐scratch cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology and Allergy, Ludwig Maximilian University of Munich, Munich, Germany.
- Department of Dermatology and Allergy, Augsburg University Hospital, Augsburg, Germany.
- Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Berne, Switzerland.
- Allergy and Immunology Unit, Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Department of Dermatology, Hospital Universitari de Bellvitge, University of Barcelona, Barcelona, Spain.
- Department of Dermatology, Venereology, and Allergology and French Expert Centre on Pruritus, University Hospital of Brest, Brest, France.
ORCID-Profile: Andreas Wollenberg, Dagmar Simon, Kanokvalai Kulthanan, Ignasi Figueras-Nart, Laurent Misery, Nithi Tangsirisap, Lara Spina, Na Lu, Susanne Grond, Kilian Eyerich
Förderung
- Eli Lilly and Company
Zitieren
APA
Wollenberg, A., Simon, D., Kulthanan, K., Figueras-Nart, I., Misery, L., Tangsirisap, N., Spina, L., Lu, N., Grond, S., & Eyerich, K. (2024). Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19669
Vancouver
Wollenberg A, Simon D, Kulthanan K, Figueras-Nart I, Misery L, Tangsirisap N, et al. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. Journal of the European Academy of Dermatology and Venereology. 2024. doi:10.1111/jdv.19669
BibTeX
@article{Wollenberg2024,
author = {Wollenberg, Andreas and Simon, Dagmar and Kulthanan, Kanokvalai and Figueras-Nart, Ignasi and Misery, Laurent and Tangsirisap, Nithi and Spina, Lara and Lu, Na and Grond, Susanne and Eyerich, Kilian},
title = {Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2024},
doi = {10.1111/jdv.19669}
}
EUVIMED